Bibliography
- STAATS PS, YEARWOOD T, CHARAPATA SG et al.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or aids. JAMA (2004) 291:63–70.
- KEDLAYA D, REYNOLDS L, WALDMAN S: Epidural and intrathecal analgesia for cancer pain. Best Pratt Res. Clin. Anaesthesia (2002) 16:651–665.
- WERMELING D, DRASS M, ELLIS D et al.: Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. j Pharmacy]. (2003) 43:624–636.
- MALMBERG AB, YAKSH TL: Effect of continuous intrathecal infusion of omega-conopeptide N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain (1995) 60:83–90.
- BOWESOX SS, GADBOIS T, SINGH T et al.: Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. Pharmac. Exp. Ther: (1996) 279:1243–1249.
- WANG YX, PETTUS M, GAO D et al:Effects of intrathecal administration of ziconotide, a selective N-type calcium channel blocker, on mechanical allodynia and hyperalgesia in a rat model of postoperative pain. Pain (2000) 84:151–158.
- ATANASSOFF PG, HARTMANNSGRUBER MW, THRASHER J et al.: Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg. Anesth. Path Med. (2000) 25:274–278.
- MARTHUR VS: Ziconotide: a new pharmacological class of drugs for the management of pain. Semin. Anesth. (2000) 19:67–75.
- BORGLAND SL, CONNOR M, OSBORNE PB, FURNESS JB, CHRISTIE MJ: Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J. Biol. Chem. (2003) 278:18776–18884.
- VALENZANO KJ, GRANT ER, WU G et al.: N-(4-tertuartbutylphenyl) 4 (3 chloropyridin-2-yfltetrahydropyrazine-1(2H)-carboxamide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. In vitro characterization and pharmacokinetic properties. J. Pharmaca Exp. Ther. (2003) 306:377–386.
- POMONIS JD, HARRISON JE, MARK L et al.: N-(4-tertuartbutylphenyfl-4- (3-chloropyridin-2- yl) tetrahydropyrazine- 1 (2H) -carboxamide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammation and neuropathic pain. Pharmaca Exp. Ther: (2003) 306:387–393.